The Scientific Research and Development team at Byondis is dedicated to advancing novel treatments for cancers and autoimmune diseases. This multidisciplinary team focuses on pioneering next-generation antibody-drug conjugates (ADCs), creating proprietary linker-drug (LD) technology, and developing site-specific conjugation methods. Their expertise extends to monoclonal antibodies (mAbs) and highly selective small molecules, ensuring precision in disease targeting. This team plays a pivotal role in translating molecular innovations into life-saving therapies with high efficacy and low systemic toxicity.
Anja Scholzen
Senior Scientist Biomarker Dev...
Deborah Hol-Schop
Principal Scientist USP
Fred Dijcks
Principal Scientist
Mark Eggink
Principal Scientist
Myrthe Rouwette
Senior Scientist Bioanalysis &...
Patrick Groothuis
Principal Scientist, In Vivo P...
Richard Postma
Senior Scientist / DSP Special...
Tanja van Achterberg
Project Leader / Senior Scient...
Tinie van Boekel
Senior Research Scientist
Willem-Jan Karstens
Principal Scientist